Document is current
Any future updates will be listed below
-
Authors
Ma, Xingyu https://orcid.org/0009-0001-2682-1021
Zhang, Wei
Zeng, Miao
Asavasupreechar, Teeranut
Kang, Synat https://orcid.org/0000-0001-6898-5289
Li, Yisheng https://orcid.org/0000-0001-8015-7128
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82030076，82470229)
- License Information
-
More Information
Article History
Received: 5 September 2024
Revised: 6 November 2024
Accepted: 11 November 2024
First Online: 22 November 2024
Competing interests
: The authors declare that the patent for the CLDN18.2-specific CAR-T therapy is held by Shenzhen Haoshi Biotechnology Co., Ltd, which also provided material support for this study. The authors have no other conflicts of interest to disclose.
: All methods in this study were performed in accordance with the relevant guidelines and regulations. All animal care and experimental procedures were conducted according to the guidelines approved by the Institutional Animal Care and Use Committee of Shenzhen University Medical School (IACUC-202400138).
